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RadiotherapyAbstract Objective: The objective of our study was to investigate the changes of apparent diffu-
sion coefﬁcient (ADC) values in prostate cancers before and after radiotherapy at 1.5 T using a
phased-array coil.
Materials and methods: Twenty-ﬁve patients with biopsy-proven prostate cancer who received
radiotherapy underwent diffusion-weighted imaging (DWI) at 1.5 T and were included in the study.
Biopsies in all patients were performed before the initial MRI examination (range, 15–30 days
before MRI; mean, 21.1 days). All 25 patients underwent DWI (b values = 0 and 1000 s/mm2)
before and 1–3 months after the completion of radiotherapy. The changes in ADC values were mea-
sured for cancers and benign tissues before and after therapy. Additionally, the changes in serum
prostate-speciﬁc antigen (PSA) levels were evaluated before and after therapy.
Results: The mean ADC value after therapy (1.418 · 103 mm2/s) was increased compared with
the mean ADC value before therapy (0.756 · 103 mm2/s) (p< 0.001) in cancer prostate. After
radiotherapy, the mean ADC values of benign peripheral zones and of benign transition zones were
statistically signiﬁcantly decreased compared with those before radiotherapy (p< 0.05). Before
treatment, a signiﬁcant difference of ADC values between the tumors and benign tissues was found
(p< 0.001), whereas there was no signiﬁcant difference of ADC values between them after treat-
ment (p> 0.5). The median PSA level after therapy (1.39 ng/mL) was decreased compared with
the median PSA level before therapy (27.20 ng/mL).
Conclusion: With the use of a 1.5-T MR scanner, our preliminary results suggest that ADC values
may be useful as a non-invasive imaging biomarker for monitoring therapeutic response of prostate
cancer to radiotherapy.
 2014 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier
B.V. All rights reserved.1. Introduction
Prostate cancer is the second most common cancer and the
sixth leading cause of cancer death among men worldwide.
The disease is generally diagnosed early, when disease is locallyed.
Table 1 Distributions of Gleason scores in 25 patients.
Gleason score Number of patients Percentage (%)
4 5 20.00
5 6 24.00
6 10 40.00
7 2 8.00
8 2 8.00
184 M.H. Wahba, M.M. Moradconﬁned to the prostate gland, without regional involvement of
pelvic lymph nodes or distant metastases to abdominal lymph
nodes or other organs beyond the prostate gland (1). Radio-
therapy for prostate cancer is currently one of the common
treatment strategies if the cancer is detected at an early stage
and invasive surgical resection can be avoided (2). Determina-
tion of the serum prostate-speciﬁc antigen (PSA) level has been
widely used for screening, diagnosis, determination of progno-
sis, and selection of the appropriate treatment for men with
clinically localized prostate cancer (3). After radiotherapy,
monitoring PSA levels is used to determine the effectiveness
of treatment as an early and accurate surrogate. However,
PSA monitoring has been shown to have a limited role in deﬁn-
ing cancer cure within the ﬁrst 5 years after radiotherapy
because, although a lower PSA nadir after radiotherapy has
been associated with cancer cure, the treatment ultimately fails
in 5–25% of patients even in those with the most optimal bio-
chemical response. In addition, the most appropriate biochem-
ical deﬁnitions of treatment failure after radiotherapy remain
controversial because of substantial differences in the diagnos-
tic accuracies of biochemical levels for predicting clinical out-
come. Moreover, no pattern of PSA kinetics after
radiotherapy has conclusively differentiated between local
and distant failure (4). To the contrary, a functional MR tech-
nique such as diffusion-weighted imaging (DWI) may detect
and localize prostate cancer before radiotherapy and then
may provide qualitative or quantitative information for mea-
suring therapeutic response in patients with prostate cancer
during and after radiotherapy (5). With the introduction of
higher-ﬁeld-strength MR scanners and the parallel imaging
technique for prostate MRI, DWI has been shown to have sev-
eral potential beneﬁts for the assessment of tumor localization
and staging. In comparison with the use of conventional MRI,
DWI can noninvasively show the changes of cellularity in
malignant tumors in the body; ADC maps can show the mobil-
ity of water in tissues .After the treatment of malignant tumors,
the cellularity and cell membrane integrity in necrotic tumor
cells are reduced and there is a subsequent increase in water
mobility, whereas viable tumor cells restrict diffusion of water
molecules (6). Several clinical studies on the usefulness of
DWI as a measurement of treatment response had been
reported (7,5,6,8,9). In their study Iraha et al., 2012 (10) con-
cluded that signal intensity on DWI appears to correlate with
PSA levels in patients with prostate cancer treated with radia-
tion therapy. Few studies have been reported for the evaluation
of changes of ADC values after radiotherapy in localized pros-
tate cancer (11,12).
Therefore, the purpose of this study was to investigate the
changes of ADC values in prostate cancers before and after
radiotherapy.
2. Patients and methods
2.1. Patients
Between November 2013 and June 2014, 25 patients with
biopsy-proven prostate cancer underwent external beam radio-
therapy and MR examinations at 1.5 T before and after radio-
therapy .The study was approved by the hospital ethics and all
the patients had been informed about the purpose of the study.
The median patient age was 70.88 years (age range, 64–
89 years).TRUS guided biopsy was done to all patients prior to MRI
examination, There was a minimum 15 days interval between
MRI and biopsy. The ﬁnal diagnoses were made by histopa-
thological examination. Based on the result of histopatholo-
gical examination of the included patients in the study, the
median Gleason score before therapy was 6 (range, 4–8).
Table 1 presents the distributions of Gleason scores. All MR
scans were obtained before the start of radiotherapy and 1–
3 months (mean, 1.5 month) after the completion of therapy.
Clinical response was determined from measurements of
serum PSA levels. The mean serum PSA level was 27.20 ng/
mL (range, 4.25–165 ng/mL) before biopsy and 1.39 ng/mL
(range, 0.25–2.1 ng/mL) after the completion of radiotherapy.
2.2. Radiotherapy
All patients received external beam radiotherapy administered
at 2 Gy/fraction to a total dose of 66–74 Gy (median dose,
70 Gy) with the use of a 15-MV linear accelerator. Patients
were treated with the use of 3D conformal radiotherapy to
the prostate only.
2.3. MR techniques
Conventional MRI and diffusion MR imaging were performed
using Philips achieva XR 1.5-T system using a torso XL 16
channels phased array coil. The MRI examination was timed
at least 2 weeks after biopsy and prior to radiotherapy treat-
ment, however the post treatment examination was held at
least one month after completion of therapy. Before scanning,
each patient received an intramuscular injection of 20 mg of
butyl scopolamine to suppress bowel peristalsis; no bowel
preparation was performed. T2-weighted turbo spin-echo
images were acquired in three orthogonal planes (axial, sagit-
tal, and coronal). The T2-weighted imaging parameters were
as follows: TR range/TE range, 2690–3800/80–90; slice thick-
ness, 3 mm; inter-slice gap, 0.3–1 mm; 512 · 304 matrix; ﬁeld
of view (FOV), 20 cm; number of signals acquired (NSA), 4;
sensitivity-encoding (SENSE) factor, 2; voxel size,
0.35 · 0.59 · 3 mm; slice number, 36; and acquisition time of
each plane, 6 min.
DW images were acquired in the axial plane using the sin-
gle-shot echo-planar imaging technique. The scanning param-
eters were as follows: 2740–2750/83–85; slice thickness, 3 mm;
inter-slice gap, 1 mm; matrix, 112 · 110; FOV, 20 cm; SENSE
factor, 2; and NSA, 6. Diffusion-encoding gradients were
applied at b values of 0, 600, 800 and 1000 s/mm2 along the
three orthogonal directions of motion-probing gradients.
ADC maps were automatically constructed on a pixel by-pixel
basis (0 and 1000 s/mm2). The acquisition time of DWI was
within 3 min.
Fig. 1 (A) Before radiotherapy, axial T2-weighted fast spin-echo image (3680/80) shows right sided PZ hypointense focal lesion.
(T2aN0M0). (B) DWI of the prostate showing hyperintense focal lesion at the right PZ (restricted diffusion) (white arrow). (C) Before
radiotherapy, ADC map (2749/84: matrix, 112 · 110; b= 0 and 1000 s/mm2) show prostate cancer of low signal intensity in right lobe.
Mean ADC value of cancer was 0.73 · 103 mm2/s. (D) After radiotherapy, axial T2-weighted fast spin-echo image (3680/80) shows
diffusely intermediate signal of the right peripheral zone. (E) DWI showing diffuse intermediate signal of the whole gland including the
previously seen focal area of restricted diffusion. (F) After radiotherapy, axial ADC map (2749/84: matrix, 112 · 110; b= 0 and 1000 s/
mm2) the previously seen tumor area at the right PZ shows mean ADC value of 1.43 · 103 mm2/s. This ﬁnding suggests good response
for treatment.
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MRI T2 weighted imaging was used to localize cancer lesions.
ADC maps were processed using Philips MR extended work-
space. ADC values in tumors and in the peripheral zone and
transition zone of benign tissue before and after radiotherapy
were calculated by placement of regions of interest (ROIs)
.When the ROIs were drawn, great care was taken to exclude
both the neurovascular bundle and the urethra to reduce any
error in ADC calculations.
Before radiotherapy, ROIs of the tumors in the peripheral
zone and transition zone were drawn on ADC maps to include
as much of the tumor as possible. For measurement of ADC
values in the peripheral zone and transition zone of benign tis-
sue, ROIs at the contralateral side of the tumor were selected.
After radiotherapy, there was no visible residual tumor in
most cases, particularly for patients with a good response. In
this situation, ROI was drawn in the same area as that initially
used in the pre-therapy. For benign tissues, the ROIs were
drawn on the same area that was initially used in pre-radio-
therapy images.
2.5. Statistical analysis
The paired student’s t test was used to compare the ADC val-
ues of tumors and benign tissues before and after radiotherapyand to compare the mean PSA levels before and after radio-
therapy. The comparison of mean ADC values of tumors
and benign tissues before radiotherapy was performed using
the paired student’s t test. A correlation in the degree of
change between serum PSA levels and ADC values was per-
formed by use of Pearson’s correlation. Two-tailed tests were
used to calculate all p values. A p value of <0.05 was consid-
ered statistically signiﬁcant.3. Results
Before radiotherapy, the mean ROIs were 108 mm2 for tumors
(range, 10–379 mm2) and 67 mm2 for benign tissue (range, 17–
90 mm2). After radiotherapy, the mean ROIs were 97.4 mm2
for tumors (range, 10–404 mm2) and 56 mm2 for benign tissue
(range, 14–82 mm2).
On the ADC maps obtained before therapy the mean ADC
value before therapy was 0.756 · 103 mm2/s, which is signiﬁ-
cantly lower than the mean ADC value after therapy
(1.418 · 103 mm2/s) (p< 0.001) (Fig. 1) (Table 2).
After the completion of radiotherapy, there was no visible
tumor in 23 patients. However, in two patients residual tumor
was seen on ADC maps, with mean ADC value of
0.654 · 103 mm2/s compared to mean ADC value of
0.875 · 103 mm2/s before treatment, correlation with total
PSA level revealed no decrease after completion of therapy,
Table 2 Results of mean apparent diffusion coefﬁcient (ADC) values and mean PSA serum level before and after radiotherapy.
ADC value · 103 mm2/s, mean ± SD (range) Mean PSA serum level (ng/mL)
Tumors Central zone (normal) Peripheral zone (normal)
Before radiotherapy 0.756 ± 0.088 1.507 ± 0.098 1.688 ± 0.132 27.20
After radiotherapy 1.418 ± 0.087 1.435 ± 0.093 1.576 ± 0.106 1.396
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treatment and 15.5 ng/mL after completion of treatment while
the other patient had a PSA serum level of 66.5 ng/mL before
treatment and 50.4 ng/mL after (Fig. 2).
Before radiotherapy, the mean ADC values of tumors in
both the peripheral zone and transition zone were statistically
lower than the corresponding values of benign tissues
(p< 0.001). After radiotherapy, a signiﬁcant difference of
ADC values between the tumors and benign tissues was not
found (p> 0.5). The mean ADC values of the peripheral zone
and transition zone of benign tissue were statistically decreased
compared with the corresponding values before radiotherapy
(p< 0.05).
Mean PSA level before therapy was 27.20 ng/mL, which is
signiﬁcantly higher than the mean PSA level of 1.396 ng/mLFig. 2 (A) Before radiotherapy, axial T2-weighted fast spin-echo
image (3680/80) shows diffuse hypointensity of the prostatic gland
with focal bulge and extracapsular extension noted at the left side
(white arrow). (T3bN0M0). (B) Before radiotherapy, ADC map
(2749/84: matrix, 112 · 110; b= 0 and 1000 s/mm2) ROI was
drawn on the most suspicious part at the left peripheral zone
showing mean ADC value of 0.60 · 103 mm2/s. (C) After
radiotherapy, axial T2-weighted fast spin-echo image (3680/80)
still shows diffusely hypointense signal of whole gland. (D) After
radiotherapy, axial ADC map (2749/84: matrix, 112 · 110; b= 0
and 1000 s/mm2) shows a slight increase in the extent of the
predominant left sided hypointensity with the calculated mean
ADC value of 0.55 · 103 mm2/s. This ﬁnding suggests poor
response for treatment as correlated with PSA serum levels (before
radiotherapy 104.0 ng/mL; after radiotherapy, 15.5 ng/mL).after therapy. A correlation in the degree of changes between
the PSA levels and ADC values was not found (p> 0.028).
With the aid of T2 MRI images, staging of the localized
prostate cancer was possible resulting in: 16 patients with stage
T2a, 2 patients with stage T2b, 2 patient with T2c stage, 2
patients staged T3a, and 3 patients with T3b. All patients
had no lymph node or distant metastases (N0M0). BPH was
found to be associated with 5 of the cancer prostate diagnosed
patients in our study (Fig. 3) (Table 3).
In 25 patients 23 patients were diagnosed with PZ tumors
while only 2 were found to have the tumors seated at the CZ
(Fig. 4).
4. Discussion
Diffusion-weighted MRI (DWI) is a noninvasive technique
with which variations in the Brownian movement of water
molecules are depicted and quantiﬁed with an apparent diffu-
sion coefﬁcient (13,14). Water diffusion in biologic tissues cor-
relates inversely with tissue cellularity and the integrity of cell
membranes (15,16). Radiation therapy is one of the major rad-
ical treatment options for achieving curative treatment of local
disease (17).
Determination of the serum prostate-speciﬁc antigen (PSA)
level has been widely used for screening, diagnosis, determina-
tion of prognosis, and selection of the appropriate treatment
for men with clinically localized prostate cancer (3). Moreover,
no pattern of PSA kinetics after radiotherapy has conclusively
differentiated between local and distant failure (4).
Normal prostate tissue is composed of an abundant glandu-
lar component that has relatively unhindered motion of water
molecules (15,16) and thus has a high ADC. Malignant tumors
of the prostate typically have higher cellular density and more
intercellular and intracellular membranes, which restrict the
movement of water molecules, causing a low ADC (15).
The ADC is measured noninvasively by DWI and is known
to increase in response to treatment in both humans and ani-
mal models for, diseases such as breast cancer (18), ﬁbrosar-
coma (19), liver tumor (20), and small-cell lung cancer (21)
and other studies which have shown that the ADC changes
during early treatment in association with response to tumor
therapy. The results conﬁrmed the potential ability of DWI
to measure early response in tumor to chemotherapy or radio-
therapy (22).
The aim of the present study was to determine the useful-
ness of diffusion weighted imaging represented by ADC as a
biomarker for evaluation of response to external beam radia-
tion therapy for prostate cancer patients.
In our study, we followed the recommendation of the study
done by Kim et al., 2009 (15), which stated that a period of 2–
3 weeks is recommended between prostate transrectal biopsy
and MRI examination to avoid the possible post biopsy hem-
orrhage effects. Another previous study by Qayyum et al.,
2004 (23) recommended a longer time interval of 6–8 weeks.
Fig. 3 (A) Before radiotherapy, axial T2-weighted fast spin-echo
image (3680/80) shows right sided PZ hypointense focal lesion
(gray arrow). Note the thinning out of the peripheral zone over the
hypertrophied central gland (associated BPH). (T2aN0M0). (B)
Before radiotherapy, ADC map (2749/84: matrix, 112 · 110;
b= 0 and 1000 s/mm2) showed prostate cancer of low signal
intensity in the right lobe. Mean ADC value of cancer was
0.73 · 103 mm2/s. (C) After radiotherapy, axial T2-weighted fast
spin-echo image shows diffusely intermediate signal of the right
peripheral zone. (D) After radiotherapy, axial ADC map (2749/84:
matrix, 112 · 110; b= 0 and 1000 s/mm2) the previously seen
tumor area at the right PZ shows mean ADC value of
1.43 · 103 mm2/s. This ﬁnding suggests good response for
treatment.
Table 3 T staging of cancer prostate patients.
T stage Number of patients Percentage (%)
T2a 16 64
T2b 2 8
T2c 2 8
T3a 2 8
T3b 3 12
Fig. 4 A 66-year-old man with right-sided CZ prostate cancer.
PSA level: before radiotherapy, 12.0 ng/mL; after radiotherapy,
2.5 ng/mL. Right central zonal prostatic adenocarcinoma, Glea-
son grade was 2 + 3. (A) Before radiotherapy, axial T2-weighted
fast spin-echo image (3680/80) shows right sided CZ hypointense
focal lesion (white arrow) (T2aN0M0). (B) Before radiotherapy,
ADC map (2749/84: matrix, 112 · 110; b= 0 and 1000 s/mm2)
shows prostate cancer of low signal intensity in right CZ. Mean
ADC value of cancer was 0.79 · 103 mm2/s. (C) After radiother-
apy, axial T2-weighted fast spin-echo image shows intermediate
signal of the previously hypointense right CZ focal lesion (white
arrow). (D) After radiotherapy, axial ADC map (2749/84: matrix,
112 · 110; b= 0 and 1000 s/mm2) the previously seen tumor area
at the right PZ shows mean ADC value of 1.42 · 103 mm2/s. This
ﬁnding suggests good response for treatment.
Role of diffusion-weighted MRI 187Hemorrhage in the prostate after a biopsy may decrease ADC
values in benign tissues. This can affect the tissue contrast on
DWI between cancer and benign tissue, which in turn may
decrease the diagnostic accuracy of cancer prediction. Further-
more, this can increase imaging distortion because of suscepti-
bility artifacts (23).
To date, several studies including ours have shown that the
ADC values of prostate cancer are lower than the ADC values
of benign noncancerous tissue (24,22,5). In our study, the mean
ADCvalue before therapywas 0.756 · 103 mm2/s, and showed
a signiﬁcant increase in patients after receiving radiotherapy
compared to its value before treatment (p< 0.001).This result
is in line with the study performed by Takayama et al., 2008
(11). Also this was in agreement with the results tested on a
3-T MRI system by Song et al., 2010 (12).ADC values of prostate cancer increased statistically in both
the peripheral zone and transition zone after radiotherapy.
Compared to ADC values of benign prostatic tissue, we found
that ADC values of tumors were signiﬁcantly lower
(p< 0.001). That result was supported by the results from
Pickles et al., 2006 and Tamada et al., 2008 (8,25).
After radiotherapy, a signiﬁcant difference of ADC values
between the tumors and benign tissues was not found
(p> 0.1).
In this study our results showed a statistically signiﬁcant
decrease in the ADC values for the peripheral zone and tran-
sition zone of benign noncancerous tissue after radiotherapy,
this was in line with the results of Song et al., 2010 study
(12), who used 3-T DWI for assessing the therapeutic response
to radiotherapy in 49 patients with 57 prostate cancers show-
ing that the mean posttherapy ADC values for the tumors
(1.61 · 103 mm2/s) increased compared with the mean pre-
therapy ADC values (1.0 · 103 mm2/s) (p< 0.001). After
treatment, there was no signiﬁcant difference in the ADC val-
ues of tumors and benign tissues.
However this was in disagreement with Takayama et al.,
2008 (11) who found that there was no difference between
ADC values of benign noncancerous prostatic tissue before
and after radiotherapy. A possible explanation for this result
is that benign prostate tissue might show histologic changes
of acinar distortion and atrophy as well as stromal ﬁbrosis
188 M.H. Wahba, M.M. Moradwith granulation tissue formation that may cause a decrease of
ADC values. Furthermore, a decrease of ADC values in
benign prostate tissue after radiotherapy might result from a
decrease in the extracellular space due to inﬂammatory swell-
ing of cells associated with radiotherapy (12).
In our study, two patients showed no increase in ADC after
radiotherapy, one patient had adenocarcinoma Gleason score
5 + 3, T3bN0M0, the other had adenocarcinoma Gleason
score 4 + 3 T3aN0M0. Correlation with PSA serum levels
proved non response to treatment.
There are few limitations to this study. First, there was no
histopathological examination of the patients after receiving
radiotherapy. Second, we used phased array coil in our study,
Endorectal coil examination was not available. In many insti-
tutions, various methods are applied for prostate DWI using
various b factors. As a consequence, various ADC values have
been reported for prostate cancer.
Compared with the use of 1.5 T, the use of 3 T has several
advantages (21). Theoretically, the signal-to-noise ratio (SNR)
increased twofold on moving from 1.5 to 3 T, and an increased
SNR can be translated into improvements in spatial, temporal,
and spectral resolution. So a possible increase in the accuracy
of MRI for prostate cancer localization and of the measure-
ments of ADC values in prostate cancers using ROIs may be
expected (12).
To conclude, in our opinion, ADC could be used as a bio-
marker for assessment of response to radiotherapy in patients
with prostate cancer; however it should be a noninvasive com-
plementary tool beside the already used biomarkers, and we
suggest that ADC maps’ images should be interpreted in con-
junction with conventional sequences to make the most out of
the examination.Conﬂict of interest
None.
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